의료기기 이야기

Emergo에서 아래와 같이 웨비나를 개최한다.​▶ 주제: Regulation (EU) 2024/1860 and IVDR Compliance in Europe▶ 일시: 2024년 10월 16일 CST 9시 (한국시간: 10월 16일 23시)  Are you an IVD medical device manufacturer who needs a better understanding of what action you will need to take and when so that you can make use of the extension under the revised Regulation (EU) 2024/1860. The European Commission amended the In Vitro Diagnost..

BackgroundIn China, a series of State Orders have been promulgated to establish the legislative basis for medical device requirements. The current State Order is State Council Order No. 739, Regulations for the Supervision and Administration of Medical Devices.The NMPA has published a draft Medical Device Management Law (Aug. 28,) for public comment.  Proposed Medical Device Legislative Changes ..

While it was a whirlwind of less than 25 minutes for five lofty learning objectives on global regulatory strategy, we felt all the topics were seminal. A synopsis of one part of our presentation follows. The importance of a well-defined intended purpose and indications for useAs we continue to observe issues related to the intended purpose/use and indications for use, we emphasized the importanc..

Gamification is the planned use of game-like elements (such as virtual reality games, indoor games, interactive quizzes, progress tracking and rewarding with scores, badges and motivation feedback) to motivate individuals to engage in non-game activities. When considering the healthcare environment (for treatment, medication tracking and mental or physical wellbeing), including gamification can ..

After announcing the implementation of minor technical changes to the instructions for the required malfunction summary reporting format in alignment with the current version of Form FDA 3500A, the U.S. Food and Drug Administration (FDA) has finalized its 2022 draft guidance document, Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers. This resource outlines the principles ..

BackgroundMedical device manufacturers must conduct appropriate testing to demonstrate that their devices are appropriately safe and effective before sale in the US. In many cases some animal and/or microorganism testing, such as to demonstrate biocompatibility, is required to obtain U.S market authorization.In February 2024, the U.S. Food and Drug Administration (FDA) noted concern that some th..

On September 18, Robert Reid, Ph.D. Deputy Director, Innovative Devices at the Medicines and Healthcare products Regulatory Agency (MHRA), updated the RAPS audience on the current status of the UK legislation. To our knowledge, this is one of the most recent updates from the MHRA. The first half of 2024In January 2024, the MHRA shared a roadmap for 2024-2025. The roadmap proposed regulatory refo..

Returning from a long holiday and need to catch up on EU medical device and IVD regulatory developments? Read our update on European regulatory news over the last few months. Amending legislation published to extend the transition of legacy IVDs and roll out EUDAMEDRegulation 2024/1860 was officially released to extend the transition time for legacy IVDs, roll out EUDAMED, and require data on di..

We last wrote about the U.S. FDA eSTAR when it became compulsory for 510(k)s. At the time, the eSTAR was voluntary for De Novos. Background on De NovosThe De Novo Classification Request “De Novo” is the regulatory mechanism used when manufacturers have a novel medical device that they expect is not high risk and so should be Class II (special controls and general controls) or Class I (general co..

In its August 22 webinar, the U.S. Food and Drug Administration (FDA) discussed the Stage 1 requirements imposed on laboratory-developed test (LDT) manufacturers.U.S. FDA Final Rule on LDTsLDTs are in vitro diagnostic devices (IVDs) that are designed, manufactured and used within a single clinical laboratory and were placed under enforcement discretion in 1976 with the medical device amendments ..